Pharmacotherapy of Urinary Retention and Urinary Incontinence

1. Learning Objectives

By the end of this chapter, the learner should be able to:

Differentiate the types of urinary incontinence and the principal causes of urinary retention.

Describe the neuropharmacology of the lower urinary tract during storage and voiding.

Select first-line and second-line medicines with correct dosing, monitoring, and safety parameters.

Adapt therapy for older adults, pregnancy and lactation, chronic kidney disease, liver disease, and polypharmacy.

Recognize indications for urological referral and for non-pharmacological interventions.

2. Physiology and Pharmacologic Targets

2.1 Storage Phase

During bladder filling, sympathetic and somatic pathways dominate. Activation of beta-3 adrenoceptors in detrusor smooth muscle causes relaxation and increases bladder capacity. Activation of alpha-1 adrenoceptors in the bladder neck and prostate increases outlet resistance. Somatic nicotinic input maintains external urethral sphincter tone.

2.2 Voiding Phase

During micturition, parasympathetic pathways dominate. Muscarinic M3 receptor activation in detrusor smooth muscle produces contraction, accompanied by coordinated relaxation in the internal and external urethral sphincters.

Pharmacologic targets therefore include muscarinic M3 receptors, beta-3 adrenoceptors, alpha-1 adrenoceptors, 5-alpha-reductase, direct muscarinic agonists, onabotulinumtoxinA, vasopressin V2 receptors, and central serotonergic–noradrenergic mechanisms.

3. Urinary Retention: Causes and General Management

Common causes of urinary retention include obstructive etiologies such as benign prostatic hyperplasia, urethral stricture, pelvic mass, and severe constipation; neurogenic or myogenic detrusor underactivity including diabetic autonomic neuropathy, spinal cord lesions, and postoperative states; and medication-induced cases from antimuscarinic agents, opioids, tricyclic antidepressants, alpha-adrenergic agonists, and calcium-channel blockers.

Acute urinary retention requires prompt bladder decompression by catheterization, evaluation of precipitating factors, and directed therapy toward the underlying cause.

4. Medicines for Urinary Retention

4.1 Alpha-1 Adrenergic Receptor Antagonists

These medicines relieve bladder outlet obstruction due to benign prostatic hyperplasia.

Representative agents and usual adult dosing (once daily unless noted):

Tamsulosin 0.4 milligrams; may increase to 0.8 milligrams if required.

Alfuzosin extended-release 10 milligrams.

Silodosin 8 milligrams with food; use 4 milligrams if creatinine clearance is 30 to 50 millilitres per minute.

Doxazosin 1 milligram, titrated to 4 to 8 milligrams.

Terazosin 1 milligram, titrated to 5 to 10 milligrams.

Mechanism of action: Selective blockade of prostatic and bladder-neck alpha-1A receptors reduces smooth-muscle tone, lowers outlet resistance, and improves urinary flow.

Pharmacokinetics: Extensive hepatic metabolism via cytochrome P450 3A4 and 2D6; once-daily formulations improve adherence.

Adverse effects: Dizziness, postural hypotension, fatigue, nasal congestion, and retrograde ejaculation (more frequent with tamsulosin and silodosin). Intraoperative floppy iris syndrome may occur during cataract surgery.

Contraindications and cautions: Avoid in severe hypotension. Use silodosin with caution in moderate renal impairment and avoid in severe renal or hepatic impairment.

Clinically important interactions: Strong inhibitors of cytochrome P450 3A4 such as ketoconazole and ritonavir increase exposure. Concomitant use with phosphodiesterase-5 inhibitors may potentiate hypotension.

Special populations: Older adults have increased fall risk; initiate at the lowest effective dose. Renal adjustment is required for silodosin; other agents have minimal renal adjustment needs.

Evidence summary: Alpha-1 antagonists provide rapid symptom relief within days, improve symptom scores and peak urinary flow, but do not reduce prostate volume.

4.2 5-Alpha-Reductase Inhibitors

Agents and dosing include finasteride 5 milligrams once daily and dutasteride 0.5 milligrams once daily.

Mechanism of action: Inhibition of conversion of testosterone to dihydrotestosterone reduces androgenic stimulation of the prostate, leading to approximately twenty to twenty-five percent reduction in volume over six to twelve months.

Adverse effects: Decreased libido, erectile dysfunction, ejaculatory disorders, and gynecomastia. Prostate-specific antigen decreases by approximately fifty percent; adjust cancer-screening interpretation accordingly.

Safety considerations: Clinical benefit is slow in onset and greatest in prostates of at least thirty to forty millilitres or with prostate-specific antigen at least 1.5 nanograms per millilitre. Teratogenic to the male fetus; women should not handle crushed tablets.

Evidence summary: Long-term use reduces risk of acute urinary retention and the need for surgery. Combination with an alpha-1 antagonist improves outcomes in large prostates.

4.3 Direct Muscarinic Agonist for Detrusor Underactivity without Obstruction

Bethanechol dosing is ten to twenty-five milligrams by mouth three to four times daily, titrated to effect.

Mechanism of action: Direct muscarinic M3 receptor agonism induces detrusor contraction.

Adverse effects: Sweating, flushing, abdominal cramps, diarrhea, bronchospasm, bradycardia, and hypotension.

Contraindications: Mechanical obstruction, asthma or chronic obstructive pulmonary disease, peptic ulcer disease, hyperthyroidism, and significant cardiac disease.

Comment: Use only after exclusion of obstruction; modern evidence of efficacy is limited.

4.4 Phosphodiesterase-5 Inhibitor for Lower Urinary Tract Symptoms with Coexisting Erectile Dysfunction

Tadalafil at five milligrams once daily improves lower urinary tract symptoms and erectile function but does not reduce prostate volume. It is contraindicated with nitrates and requires caution with alpha-1 antagonists due to hypotension risk.

4.5 Non-Pharmacological Adjuncts

Clean intermittent self-catheterization for neurogenic retention, removal of precipitating medicines, and evaluation for surgical relief of obstruction when indicated.

5. Urinary Incontinence: Classification and Pharmacologic Choices

Stress urinary incontinence is leakage with increases in intra-abdominal pressure due to urethral sphincter weakness. First-line therapy is pelvic floor muscle training. Pharmacological options include duloxetine and topical vaginal estrogen in post-menopausal individuals.

Urge urinary incontinence due to overactive bladder presents with urgency with or without incontinence, often with frequency and nocturia. First-line non-pharmacological therapy is bladder training and review of fluid and caffeine intake. Pharmacological therapy includes antimuscarinic agents and beta-3 adrenergic receptor agonists; onabotulinumtoxinA is considered for refractory disease.

Mixed urinary incontinence requires combined strategies according to the predominant component. Overflow urinary incontinence requires treatment of the cause of retention, usually bladder outlet obstruction. Nocturnal polyuria with bothersome nocturia may be treated with desmopressin in carefully selected patients with mandatory sodium monitoring.

6. Medicines for Urge Urinary Incontinence and Overactive Bladder

6.1 Antimuscarinic Agents (Muscarinic M3 Receptor Antagonists)

Common agents and adult dosing:

Oxybutynin immediate-release 2.5 to 5 milligrams three times daily; extended-release 5 to 10 milligrams once daily; transdermal systems and topical gel reduce systemic adverse effects.

Tolterodine extended-release 4 milligrams once daily; immediate-release 2 milligrams twice daily.

Solifenacin 5 to 10 milligrams once daily.

Darifenacin 7.5 to 15 milligrams once daily.

Trospium 20 milligrams twice daily; extended-release 60 milligrams once daily administered on an empty stomach.

Fesoterodine 4 to 8 milligrams once daily.

Mechanism of action: Blockade of muscarinic M3 receptors in detrusor muscle reduces involuntary contractions and increases functional bladder capacity.

Pharmacokinetics: Many agents are substrates of cytochrome P450 3A4 and 2D6. Trospium, a quaternary amine, has limited penetration into the central nervous system.

Adverse effects: Dry mouth, constipation, blurred vision, tachycardia, cognitive impairment including confusion and delirium, and urinary retention.

Contraindications and cautions: Gastric retention, uncontrolled narrow-angle glaucoma, and clinically significant post-void residual urine volumes. Use caution in individuals with dementia or Parkinson disease.

Clinically important interactions: Additive anticholinergic effects with tricyclic antidepressants, first-generation antihistamines, and antipsychotics. Strong cytochrome P450 3A4 inhibitors increase exposure. High doses of solifenacin may prolong the corrected QT interval.

Special populations: In older adults, select agents with lower central nervous system penetration and use the lowest effective dose. Dose reduction is often required in renal impairment for solifenacin, tolterodine, and fesoterodine; avoid or adjust in moderate to severe hepatic impairment, especially for darifenacin and tolterodine. Evidence in pregnancy and lactation is limited; prioritise non-pharmacological therapy.

Evidence summary: Antimuscarinic agents reduce urgency and incontinence episodes by approximately one to two per day compared with placebo. Extended-release and transdermal formulations have improved tolerability and adherence.

6.2 Beta-3 Adrenergic Receptor Agonists

Mirabegron dosing is twenty-five to fifty milligrams once daily, beginning with twenty-five milligrams in older adults or in renal impairment. Vibegron dosing is seventy-five milligrams once daily where available.

Mechanism of action: Selective stimulation of beta-3 receptors relaxes detrusor muscle during bladder filling, increasing capacity without antimuscarinic adverse effects.

Adverse effects: Hypertension, nasopharyngitis, headache, and rarely urinary retention.

Contraindications and cautions: Uncontrolled hypertension. Monitor blood pressure after initiation and with dose increases.

Clinically important interactions: Mirabegron is a moderate inhibitor of cytochrome P450 2D6 and may increase exposure to metoprolol, tricyclic antidepressants, and several antidepressants.

Evidence summary: Efficacy is comparable to antimuscarinic agents with superior tolerability. Combination of mirabegron with low-dose solifenacin improves outcomes with a modest increase in adverse effects.

6.3 Intradetrusor OnabotulinumtoxinA

Dose and administration: One hundred Units injected into approximately twenty intradetrusor sites for non-neurogenic detrusor overactivity; two hundred Units for neurogenic detrusor overactivity under specialist care.

Mechanism of action: Inhibition of acetylcholine release from presynaptic terminals causes temporary chemodenervation of detrusor muscle, reducing urgency and incontinence for six to nine months.

Adverse effects: Urinary retention necessitating intermittent catheterization, urinary tract infection, hematuria, and dysuria.

Contraindications: Active urinary tract infection and inability or unwillingness to perform intermittent self-catheterization if necessary.

6.4 Desmopressin for Nocturnal Polyuria

Sex-specific dosing: Men require fifty to one hundred micrograms sublingually at bedtime; women require twenty-five to fifty micrograms sublingually at bedtime because women have greater sensitivity.

Mechanism of action: Selective V2 receptor agonism increases renal water reabsorption, reduces nocturnal urine production, and decreases nocturnal voids.

Adverse effects and monitoring: Hyponatremia can be severe. Measure serum sodium at baseline, at three to seven days, at one month, and periodically thereafter. Restrict evening fluid intake.

Contraindications: History of hyponatremia, estimated glomerular filtration rate below approximately fifty to sixty millilitres per minute, uncontrolled hypertension, heart failure, and concurrent loop diuretic therapy.

6.5 Duloxetine for Stress Urinary Incontinence in Women

Dose: Forty milligrams twice daily; consider twenty milligrams twice daily for the first one to two weeks to improve tolerability.

Mechanism of action: Inhibition of serotonin and norepinephrine reuptake enhances pudendal motor neuron activity and increases urethral sphincter tone during stress.

Adverse effects and cautions: Nausea, insomnia, fatigue, dry mouth, and rare serotonin syndrome. Contraindicated with monoamine oxidase inhibitors and linezolid; use caution with other serotonergic medicines. Not approved for this indication in all regions.

6.6 Low-Dose Vaginal Estrogens for Post-Menopausal Lower Urinary Tract Symptoms

Topical estradiol or estriol preparations improve genitourinary atrophy and may reduce urgency and frequency. Systemic exposure is minimal at low vaginal doses. Avoid in active estrogen-dependent malignancy unless approved by an oncologist.

6.7 Tricyclic Antidepressant for Selected Cases

Imipramine ten to twenty-five milligrams at bedtime may be considered for nocturnal enuresis or stress-predominant symptoms when other options fail. Use caution because of anticholinergic effects and risk of corrected QT interval prolongation and arrhythmias; generally a last-line option in adults.

7. Special Populations and Comorbidities

7.1 Older Adults

Give priority to non-pharmacological therapy. When pharmacological therapy is necessary, consider a beta-3 adrenergic agonist to minimise cognitive adverse effects. If an antimuscarinic agent is used, select one with lower central nervous system penetration and use the lowest effective dose. Reassess post-void residual volume if symptoms worsen.

7.2 Chronic Kidney Disease

Dose adjustment is required for silodosin, solifenacin, tolterodine, fesoterodine, and mirabegron in advanced impairment. Desmopressin is generally avoided when estimated glomerular filtration rate is below approximately fifty to sixty millilitres per minute because of hyponatremia risk. Alpha-1 antagonists and 5-alpha-reductase inhibitors usually require no renal dose adjustment.

7.3 Liver Disease

Many agents for overactive bladder undergo hepatic metabolism. Use the lowest effective doses, consider trospium which has less hepatic metabolism, and monitor for toxicity. Alpha-1 antagonists and 5-alpha-reductase inhibitors can be used with caution.

7.4 Pregnancy and Lactation

For stress urinary incontinence and overactive bladder during pregnancy and lactation, prefer non-pharmacological strategies. Topical vaginal estrogen may be used after childbirth for genitourinary atrophy when appropriate. Pharmacological therapy should be reserved for severe, refractory symptoms after specialist consultation.

7.5 Drug–Disease and Drug–Drug Interactions

Cumulative anticholinergic exposure increases risks of delirium, constipation, and urinary retention. Mirabegron increases exposure to medicines metabolized by cytochrome P450 2D6. Alpha-1 antagonists combined with phosphodiesterase-5 inhibitors increase hypotension risk. Medicines that prolong the corrected QT interval may interact with high-dose solifenacin or tricyclic antidepressants. Rifampicin induction may reduce exposure to several overactive bladder agents; monitor clinical response. Hyperthyroidism may potentiate tachycardia with antimuscarinic agents or beta-3 agonists.

8. Monitoring and Follow-Up

Baseline parameters include blood pressure for beta-3 agonists and alpha-1 antagonists, post-void residual volume to assess retention risk, cognitive status and fall risk before antimuscarinic therapy, and serum sodium before desmopressin. Efficacy assessment should include a bladder diary that records number of voids per day, urgency episodes, number of incontinence pads, and nocturnal voids. Safety monitoring includes dry mouth, constipation, visual disturbance, dizziness, orthostatic hypotension, changes in blood pressure, cognitive changes, post-void residual volume, and serum sodium during desmopressin therapy.

9. Practical Algorithms (Text Format Without Abbreviations)

Male with lower urinary tract symptoms and suspected benign prostatic hyperplasia: Exclude red flags such as gross hematuria, urinary tract infection, and urinary retention with renal impairment. Obtain post-void residual volume, serum creatinine, and urinalysis. If symptomatic without complications, initiate an alpha-1 antagonistic agent. If prostate volume is at least thirty to forty millilitres or prostate-specific antigen is at least 1.5 nanograms per millilitre, add a 5-alpha-reductase inhibitor. If erectile dysfunction coexists and blood pressure permits, consider tadalafil five milligrams once daily. For acute urinary retention, catheterize, initiate an alpha-1 antagonist, and perform a trial without catheter after two to three days. Refer for surgical or minimally invasive therapy if refractory or complicated.

Woman with urgency-predominant incontinence: Begin bladder training and review fluid and caffeine intake. Initiate either a beta-3 adrenergic receptor agonist or an antimuscarinic agent with the lowest anticholinergic burden appropriate to comorbidities. If response is inadequate, switch to the other class or combine low-dose solifenacin with mirabegron. If still refractory, offer intradetrusor onabotulinumtoxinA or neuromodulation under specialist care.

Stress urinary incontinence in women: Pelvic floor muscle training with or without a pessary. Add low-dose topical vaginal estrogen in post-menopausal genitourinary syndrome when appropriate. Consider duloxetine for severe symptoms after counselling regarding adverse effects. Consider surgical options if refractory.

Nocturnal polyuria and nocturia: Reduce evening fluid and salt intake and adjust timing of diuretics. Consider desmopressin with mandatory sodium monitoring as described above.

10. Dosing Reference Table (Adults)

11. Key Safety Pearls

Measure post-void residual volume before escalating antimuscarinic therapy or before intradetrusor onabotulinumtoxinA. Reduce fall risk by initiating alpha-1 antagonists at night and at the lowest effective dose. Minimise cognitive adverse effects in older adults by avoiding cumulative anticholinergic exposure and by preferring a beta-3 adrenergic agonist when suitable. Desmopressin requires strict sodium monitoring to prevent hyponatremia. When interpreting prostate-specific antigen during 5-alpha-reductase inhibitor therapy, double the measured value to approximate the true value.